Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | ABL1 T315I ABL1 R332W |
Therapy | Dasatinib |
Indication/Tumor Type | lung adenocarcinoma |
Response Type | resistant |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
ABL1 T315I ABL1 R332W | lung adenocarcinoma | resistant | Dasatinib | Preclinical | Actionable | In a preclinical study, lung adenocarcinoma cells harboring ABL1 R332W (also reported as R351W) and expressing ABL1 T315I demonstrated resistance to Sprycel (dasatinib) in culture (PMID: 26758680). | 26758680 |
PubMed Id | Reference Title | Details |
---|---|---|
(26758680) | Somatically mutated ABL1 is an actionable and essential NSCLC survival gene. | Full reference... |